Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.   Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete a
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Madison, NJ (PRWEB) , ... July 29, 2015 , ... ... and approval of combination products , in particular, drug/device combinations. The current system ... innovation by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is ... services. The core expertise of PRC Clinical is focused on Clinical Trial Management, ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... is making good progress in evaluating the full range of capabilities of its ... Adult tissue stem cells perform the day-to-day renewal and repair of normal tissues ...
(Date:7/28/2015)... ... ... Xsample 530 sample changer for vials can be used with Anton Paar density meters, ... 12,000 mPas (internal air) up to 36,000 (external air) – and can process up to ... 530 is its removable magazine, which is easily lifted off its hub and carried by ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... MIT scientists explaining how they recently discovered a catalyst ... assistance of a five-year $20 million award from the ... (Caltech) Chemical Bonding Center (CBC) project, called "Powering the ... fulfill its goal of efficiently and economically converting solar ...
... MEDX ) announced today that it is scheduled to ... a.m. Eastern Time on,Thursday, September 4, 2008. The event ... Investor Relations section of the Medarex website at, http://www.medarex.com ... available,following the event., About Medarex, Medarex is ...
... Sky One,Medical, Inc. ("China Sky One Medical" or "the ... company producing external use,over-the-counter drugs in the People,s Republic ... to list its common stock on the,NASDAQ Global Market., ... the NASDAQ Global Market on,September 15, 2008, and that ...
Cached Biology Technology:Understanding the science of solar-based energy: more researchers are better than one 2Medarex to Present at the Thomas Weisel Partners Healthcare Conference 2China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market 2China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market 3
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... bacterium that grows in the soil of potato fields can ... a common powerful pesticide used for killing worms on potatoes, ... but lucky for the environment because University of North Carolina ... particular enzyme weren't there, it would take 10,000 years for ...
... come to mind. But they are not the only kind ... as its popular cousin yet its grave situation continues to ... , Sanchez-Azofeifa is the director of the newly ... in the Faculty of Science. The Inter American Institute for ...
... homes and offices is an unaccomplished dream due to the ... The study of photosynthesis in plants could provide new clues ... reaching them, and how they transform it into other forms ... the Freie Universität Berlin, used the X-ray source of the ...
Cached Biology News:New discovery: If it weren't for this enzyme, decomposing pesticide would take millennia 2New discovery: If it weren't for this enzyme, decomposing pesticide would take millennia 3Tropical dry forests receive international recognition 2Plants reveal a secret and bring researchers nearer a cleaner future 2
Request Info...
... Tissue Array (MSTA) slides were designed to study ... from multiple species. Tissue slices from three ... which can then be treated as a single ... in situ hybridization. This format allows ...
... Xcell eukaryotic system, 100 to ... used for electroporation of mammalian ... main unit, CE module for ... square-wave pulses, ShockPod shocking chamber, ...
Request Info...
Biology Products: